CHOICE: CHanges to Treatment and Outcomes in Patients With Type 2 Diabetes Initiating InjeCtablE Therapy

NCT00635492 · Completed

Last updated 2026-05-28

The CHOICE trial studies how long people with type 2 diabetes stay on their first injectable diabetes medication over 12 and 24 months.

Status Completed The study has finished.

Type Observational

Participants 2,515 people

Who can join Ages 18+ · all sexes

Timeline Started 2008-01 · est. completion 2011-12

Where 96 sites · Denmark, France, Germany, Greece, Sweden

What this study is testing ClinicalTrials.gov NCT00635492 ↗

Description as written by the study sponsor.

Patients initiating injectable therapy for type 2 diabetes (insulin or exenatide) in usual clinical practice will be enrolled and followed up for two years in order to describe actual practice with regards to the time on initial treatment regime, whether treatment regimens are being modified, what treatment modifications are made, and clinical and patient-reported outcomes.

Treatments tested

exenatide also known as Byetta Drug

subcutaneous injection, 5mcg or 10mcg, twice a day
any human insulin or analog insulin(s) given in any regimen by subcutaneous injection Drug

Main thing measured	Estimates of Probability to Remain on Initial Injectable Treatment at 12 and 24 Months.
Sponsor	AstraZeneca
Conditions studied	Type 2 Diabetes Mellitus
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT00635492 ↗